Compare Sana Biotechnology Inc (SANA) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Target Corporation — how do they compare? Sana Biotechnology Inc trades at $2.8 (market cap $836.71M), while Target Corporation trades at $153.81 (market cap $70.31B). The key difference: Target Corporation is far larger — about 84× Sana Biotechnology Inc's market cap, and Target Corporation pays a 3% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Target Corporation for 137 Days on average.
| SANA | TGT | |
|---|---|---|
Market Cap | $836.71M | $70.31B |
Volume | 4,507,444 | 4,164,999 |
Sector | Health | Consumer Staples |
52-Week High | $5.92 | $169.90 |
52-Week Low | $2.68 | $83.68 |
Typical Hold Time | 23 Days | 137 Days |
Enterprise Value | $749.96M | $83.58B |
Dividend Yield | — | 3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Target (TGT) trades at $153.77, up 1.86% today, with a bearish technical signal but strong fundamental support. The stock shows robust earnings beats in recent quarters, with Q2 2026 EPS of $4.11 significantly exceeding the $2.35 estimate. Valuation ratios like a P/E of 16.05 and P/S of 0.65 appear attractive relative to historical averages. Recent news highlights strategic price cuts on 2,000 items to boost holiday sales and market share.
The outlook is cautiously optimistic, supported by solid profitability, dividend reliability, and analyst consensus pointing to upside. Key risks include competitive pressures, margin compression from pricing strategies, and broader retail sector volatility. The consensus price target of $167.18 suggests potential appreciation, but investors should weigh execution risks against growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
